Comparing two medicines to prevent COPD flare-ups
Treatments studied
Part of Lungs & breathing clinical trials.
This study compares two medications, roflumilast and azithromycin, to see which is better at reducing COPD flare-ups (also called exacerbations) in people with severe COPD and chronic bronchitis. If it works, it could help you have fewer flare-ups and feel better day to day.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 years or older.
- You have a diagnosis of severe COPD, as confirmed by a breathing test and your doctor.
- You have had at least 2 moderate flare-ups or 1 severe flare-up requiring hospital care in the last year.
- You are already using two inhalers (called LABA and LAMA, with or without an inhaled steroid) as your regular treatment.
- You have not had a recent flare-up or infection, and you are stable enough to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 4 study tests whether a long course of azithromycin can reduce flare-ups in people with chronic obstructive pulmonary disease (COPD) who have had recent exacerbations. It also looks at mucus properties and how flare-ups happen.
This Phase 4 study looks at optimizing how people with COPD take azithromycin to reduce flare-ups (exacerbations). If you already take azithromycin regularly, the trial may test ways to improve how it’s used safely.
This study compares two antibiotics, doxycycline and levofloxacin, to see which works better for treating COPD flare-ups. If you have a COPD exacerbation and haven't taken antibiotics recently, you may be able to join.
This study tests an experimental drug for people with moderate to severe COPD, especially those with chronic bronchitis. It aims to see how the drug affects certain markers in your body and whether it helps with your COPD symptoms.
This study tests an oral medicine called roflumilast for adults with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective when taken by mouth, and you can join if you have not used other systemic treatments recently.
This study looks at people hospitalized for a COPD flare-up (“exacerbation”). It may help improve how flare-ups are treated because participants need to receive the usual rescue medicines like steroids and/or antibiotics and then follow a study plan.
Hear when a new Chronic Obstructive Pulmonary Disease With Exacerbation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.